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ABSTRACT 
Topical instillation of eye drops remains the most common and for most the easiest route of 
ocular drug administration, representing the treatment of choice for many ocular diseases. 
Nevertheless, low ocular bioavailability of topically applied drug molecules can considerably 
limit their efficacy. Over the last several decades, numerous drug delivery systems (DDS) have 
been developed in order to improve drug bioavailability on the ocular surface. This review 
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systematically covers the most recent advances of DDS applicable by topical instillation, that 
have shown better performance on in vivo models compared to standard eye drop formulations. 
These delivery systems are based on in situ forming gels, nanoparticles and combinations of 
both. Most of the DDS have been developed using natural or synthetic polymers. Polymers offer 
many advantageous properties for designing advanced DDS including biocompatibility, gelation 
properties and/or mucoadhesiveness. However, despite the high number of studies published 
over the last decade, there are several limitations for clinical translation of DDS. The potential 
challenges for commercialization of new DDS are also presented in this review. 
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ABRREVIATIONS: 
ADME  Absorption, distribution, metabolism, and excretion 
AUC Area under the curve 
BAK Benzalkonium chloride  
Cmax Maximum concentration 
CRO Contract research organizations  
CTD Common technical document 
DDS Drug delivery system  
EB Evans blue 
EMA  European medicines agency 
EC Ethyl cellulose 
FDA Food and drug administration  
GLP Good laboratory practices  
GMPs Good manufacturing practices  
HA Hyaluronic acid 
HCl Hydrochloride 
HEC Hydroxyethyl cellulose 
HET-CAM Hen's egg-chorioallantoic membrane test 
HPLC High performance liquid chromatography 
HPMC Hydroxypropyl methyl cellulose 
IOP Intraocular pressure 
LD50 Lethal Dose, 50% 
MC Methylcellulose  
MDs Medical devices  
MPs Microparticles 
NaCMC Sodium carboxymethycellulose 
NPs Nanoparticles 
PBA Phenylboronic 
PCL Poly(epsilon-caprolactone) 
PEG Polyethylene glycol 
PEO Polyethylene oxide  
PET Positron emission tomography 
PK Pharmacokinetics  
PLA Polylactide 
PLGA Poly(lactic-co-glycolic acid) 
PMA poly(methacrylic acid) 
PMN Polymorphonuclear leucocyte 
pNIPAAm Poly(N-isopropylacrylamide) 
PPO Polypropylene oxide 
TA Triamcinolone acetonide  
ΔIOP Intraocular pressure variation 
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5-FU 5- FluoroUracil 
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1. INTRODUCTION 
 
Topical administration represents the easiest and least invasive route to deliver drugs to the 
anterior segment of the eye. Therefore, eye drops are the treatment of choice for many ocular 
diseases such as infection, inflammation, glaucoma, dry eye and allergy, representing 90% of the 
commercialized products in the global ophthalmic drug market [1]. However, the major 
limitation of topical administration remains their relatively low efficacy. Drug delivery through 
the anterior segment is limited due to the unique physiology and anatomy of the eye, providing 
low bioavailability [2] (Fig. 1).  
 
Fig. 1. Main static and dynamic barriers for ocular drug delivery. 
The first barrier of drug delivery is the limited volume (~30 µL) of the eye drop that can be 
applied onto the ocular surface, due to the limited precorneal surface area.  Moreover, most of 
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the volume applied is eliminated during the first reflex blinking, triggered by the abrupt increase 
of tear volume [3]. The remaining volume of drug left on the eye then mixes with the tear film 
produced by the lacrimal and Meibomian glands. The tear film is a thin transparent fluid layer 
composed of three phases including an outer oily phase, an intermediate aqueous phase, and an 
inner mucin layer (Fig. 1). The oily phase and the aqueous phase represent another barrier for 
hydrophilic and hydrophobic drugs, respectively. Moreover, the aqueous phase is composed of 
proteins and enzymes that can fix and degrade drugs. The inner layer of the tear fluid is 
composed of mucins that are high-molecular weight and highly glycosylated proteins secreted by 
the epithelial cells of the cornea. Their primary function is to protect the ocular surface against 
external noxious stimuli and invading pathogens. Mucins are negatively-charged 
macromolecules that can attract or repulse drugs via electrostatic interactions depending on the 
charge of the drug molecule or carrier system [4]. An additional factor that limits drug 
bioavailability is the tear film turnover (between 0.5 and 2.2 µL/min under normal conditions in 
human) increases after topical instillation, causing a rapid clearance (within 1-2 min) of the drug 
molecules via the nasolacrimal drainage [5]. Two minutes after eye drop installation, it is 
estimated that 60% of the active ingredient is eliminated via all these mechanisms. After 8 min, 
the active ingredient is diluted at 1/1000 and after 15-25 min, all the active ingredient is 
eliminated on the corneal surface [6].  
For some conditions such as glaucoma and uveitis, drugs need to diffuse through the anterior 
ocular tissues (cornea, sclera) to achieve adequate intraocular levels in order to induce their 
therapeutic effect. It is, however, estimated that less than approximately 5% of drugs applied by 
this route are can efficiently be delivered to the anterior chamber [3,7].  Corneal and 
scleral/conjunctival tissues also represent a major barrier of drug delivery into the anterior 
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chamber. The cornea is a transparent lens-shaped tissue responsible for two thirds of the 
refractive power of the eye. It is composed of three layers: the outer epithelium, the intermediate 
stroma and the inner endothelium (Fig 1). The corneal epithelium is a hydrophobic layer, 
composed of a stratified squamous cell layer. The high expression of tight junctions between 
epithelial cells forms a strong permeation barrier for hydrophilic drugs [8,9]. Also, the presence 
of drug efflux pumps and cytochrome P450 (drug-degrading enzyme) in the epithelium 
represents another cause of low drug bioavailability [10–12]. The stroma represents 90% of the 
corneal volume. In contrast to the epithelium, the stroma is highly hydrophilic, due to its high 
water content (80%), which limits the penetration of hydrophobic drugs. Finally, the 
endothelium is also considered as a hydrophobic barrier due to the presence of tight junctions; 
however, because of its lower cell thickness, the endothelium represents a weaker permeation 
barrier compared to the epithelium. The conjunctiva and sclera are tissues surrounding the 
cornea; they also consist of low-permeable barriers that limit drug permeation into the anterior 
chamber. Conjunctiva and sclera are less drug resistant compared to the cornea tissue. However, 
the presence of blood vessels promotes drug elimination via the systemic route [13].   
To improve the efficacy of drug delivery via the topical route, high drug concentrations and 
repeated instillations are often required in order to reach the desired therapeutic effects, which 
can result in side effects and poor patient compliance. [14]. Two main strategies have been 
followed in order to improve ocular bioavailability upon topical administration: a) increasing 
precorneal retention time, and b) enhancing corneal, scleral and/or conjunctival drug 
permeability.  
A variety of drug delivery systems (DDS) have been investigated and marketed during the past 
decades including prodrugs, permeation enhancers, gels, ointments and liposomes nanocarriers 
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[15]. More recent advances in nanotechnology and biomaterial sciences led to the development 
of new DDS such as in situ gelling systems, polymeric nanoparticles, polymeric/lipidic 
nanoparticles or a combination of these strategies. Most of these recent DDS have been 
developed using natural and/or synthetic polymers, which are macromolecules composed of 
many repeated subunits [16]. The physicochemical properties of polymers such as molecular 
mass, charge, hydrophobicity and type of functional groups, make them suitable material for a 
broad range of applications. In this review, we will give an overview of the recent development 
of DDS applicable by topical instillation, which showed successful results on in vivo models. 
This review will also highlight current challenges towards the commercial development of new 
DDS formulated in eye drops. 
2. In situ gelling systems 
The use of viscous formulations, such as gels and ointments, have been widely used to increase 
the retention time of drugs on the ocular surface by limiting the drug elimination via the 
nasolacrimal drainage. However, gels and ointments are less accurate and less reproducible to 
apply, and can induce blurred vision, eyelids crusting, and lacrimation [15]. More recently, 
stimuli-responsive materials have been used to develop in situ gelling systems as an alternative 
to standard liquid and viscous formulations. In situ gels are administrated as a liquid and form a 
gel upon contact of the eye. This solution-gelation (sol-gel) transition is triggered by the 
environmental stimuli of the ocular surface, including the temperature, pH and the presence of 
ions in the tear fluid (Fig. 2).  
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Fig. 2. Principle of ‘sol-gel transition’ of different types of in situ gel used for ocular drug 
delivery. (A) Schematic principle of sol-gel transition of different types of stimuli-responsive 
materials. Images of sol-gel transition of thermo-responsive PNIPAAm (from [17]) (B) and ion-
responsive gellan gum (C) (from [18]). 
Thermo-responsive, pH-responsive and ion-responsive materials are the three main types of 
stimuli-responsive materials that are most widely used for the development of gelling systems 
for ocular drug delivery (Table 1). 
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Table 1. In situ gelling systems used for ophthalmic drug delivery. 
Material Drug model Animal 
model 
 
In vivo studies In vivo results Ref 
 
Thermo-responsive gelling systems 
 
Poloxamer® 
 
Loteprednol 
 
Rabbit 
 
Determination of drug concentration of aqueous 
humor by HPLC 
 
AUC(0-10h) and Cmax values was found 2.55-fold and 4.34-fold higher, 
respectively, for in situ gel compared with marketed formulation. 
  
 
[19] 
 Methazolamide Rabbit Determination of drug concentration of aqueous 
humor by HPLC. Measurement of intraocular 
pressure by indentation tonometer. 
AUC(0-12h) was found 1.58-fold higher for in situ gel compared with Azopt®. 
No significant difference in the IOP lowering effect was found between in situ 
gel and Azopt®. 
 
[20] 
 Timolol Rabbit Biocompatibility study (slit lamp test and 
histopathology study). Determination of drug 
concentration of aqueous humor by HPLC. 
Measurement of intraocular pressure by indentation 
tonometer. 
 
Good biocompatibility and no sign of irritation. AUC(0-240min) and Cmax was 
found 1.1-fold higher and 1.33-fold lower, respectively, for in situ gel compared 
with standard eye drop. No significant difference in the IOP lowering effect was 
found between in situ gel and standard eye drop. 
 
[21] 
Poloxamer®-
HPMC or 
Poloxamer®-HEC 
 
Ciprofloxacin 
HCl 
Rabbit Assessment of antimicrobial efficacy by scoring 
system 
Significant improvement of scoring for Poloxamer-HPMC and poloxamer-HEC 
in situ gels compared with Ciprofloxacin®. 
[22] 
PNIPAAm Epinephrine Rabbit Measurement of intraocular pressure by ophthalmic 
tonometer. 
In situ gel decreased IOP for 24h with a minimum of 8.9 mmHg at 4h. Standard 
eye drop decreased IOP for 6-7h with a minimum of 7.2 mmHg at 2h. 
 
[23] 
PNIPAAm-HA Ketoconazole Rabbit Eye irritation test (Draize test). Assessment of 
antimicrobial efficacy by scoring system. 
 
No sign of ocular irritation. 91.7% and 66.7% of eyes were cured with in situ gel 
and commercial eye drops, respectively. 
[24] 
 Cyclosporine A Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in ocular tissues by HPLC. 
No sign of ocular irritation. Significant increase of drug concentration levels in 
corneas (1455.8 ng/g of tissue) compared with castor oil formulation and 
commercial eye drops. 
 
[25] 
Xyloglucan 
 
Pilocarpine Rabbit Assessment of pupil diameter. AUC(0-270min) values were found higher for in situ gel compared with 
standard solution. 
 
[26] 
Glycerol 2-
phosphate-
chitosan-gelatin 
Levocetirizine Rabbit 
and 
guinea 
pig 
Eye irritation test. Precorneal drainage assessment 
by slit lamps and blue light. Assessment of 
antiallergic conjunctivitis efficacy by Evans Blue 
(EB) extravastion quantification. 
No sign of ocular irritation. Residence time was found 2.94-fold higher for in 
situ gel compared with aqueous solution. Extravasted amounts of EB in ocular 
tissues were found 1.75-fold and 2.56-fold lower for aqueous solution and in situ 
gel, compared with physiological saline.  
[27] 
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 Timolol Rabbit Eye irritation test. Precorneal retention time by 
fluorescein staining. Measurement of intraocular 
pressure by tonometer. 
 
No sign of ocular irritation. Precorneal retention was around 10 min for standard 
eye drops and at least 60 min for in situ gel. The maximum IOP lowering effect 
was observed at 0.5h and 1h for standard eye drops and in situ gel, respectively. 
The IOP lowering effect lasted 12h and 24h for standard eye drops and in situ 
gel, respectively.  
 
[28] 
 Latanoprost Rabbit Measurement of intraocular pressure by tonometer. Weekly administration of in situ gel showed similar IOP lowering effect pattern 
compared with daily administration of Xalatan®. 
 
[29] 
pH-responsive gelling systems 
 
Carbopol®-
HPMC 
 
Puerarin 
 
Rabbit 
 
Determination of drug concentration of aqueous 
humor by HPLC. 
 
 
AUC(0-24h) and Cmax values were found 2.17-fold and 1.29-fold higher, 
respectively, for in situ gel compared with aqueous solution. 
 
 
[30] 
 Baicalin Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in ocular tissues by HPLC. 
 
AUC and Cmax values were found 6.1-fold and 3.6-fold higher, respectively, for 
in situ gel compared with aqueous solution. 
 
[31] 
 Pefloxacin Rabbit Determination of drug concentration in ocular 
tissues by HPLC. 
Drug concentration was found above MIC (minimum inhibitory concentration, 2 
ng/mL) for 24h for in situ gel and for 12h for marketed eye drops. 
 
[32] 
 Timolol and 
brimonidine 
Rabbit Eye irritation test. Measurement of intraocular 
pressure by Schiotz tonometer. 
No sign of ocular irritation. Maximum ΔIOP (IOP treated eye – IOP untreated 
eye) achieved 17.75±0.050 mmHg at 12h and 13.12±0.034 mmHg at 4h for in 
situ gel and COMBIGEN®, respectively. 14h after instillation, ΔIOP was found 
2.51-fold higher for in situ gel compared with COMBIGEN®. 
   
[33] 
Carbopol®-
Chitosan 
Timolol Rabbit Measurement of intraocular pressure by Schiotz 
tonometer. 
AUC(0-9h) values were found 1.71-fold and 2.48-fold higher for Carbomer® in 
situ gel and Carbomer®-Chitosan in situ gel, respectively, compared with 
GLUCOMOL®. 
 
[34] 
Ion-responsive gelling systems 
 
Gellan gum 
 
Moxifloxacin 
 
Rabbit 
 
Determination of drug concentration in ocular 
tissues by HPLC. Bacterial infection study. 
 
AUC(0-∞) and Cmax values were found 6-fold higher for in situ gel compared 
with Vigamox®. In situ gel cured corneal infection after 4 days compared to 7 
days of photodynamic therapy. 
 
 
[35] 
 Brinzolamide Rabbit Eye irritation test (Draize test). Measurement of 
intraocular pressure by tonometer. 
1h after instillation, IOP was found 18.2% and 27% lower for in situ gel and 
standard solution, respectively. After 6h, IOP was found lower for in situ gel 
(18.6 mmHg) compared to standard solution (21.2 mmHg). 
 
[18] 
Gellan gum-
NaCMC 
Gatifloxacin Rabbit Eye irritation test (Draize test). Assessment of 
antimicrobial efficacy on a S. aureus infection 
model by clinical symptoms scoring. 
No sign of ocular irritation. Significant improvement in the observed symptoms 
for in situ gel compared with marketed solution. 
[36] 
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Gellan gum-K-
carrageenan 
Econazole Rat Eye irritation test (HET-CAM). Biopermanence 
PET study 
No sign of ocular irritation. AUC(0-∞) was found 2.33-fold higher for in situ gel 
compared to standard solution. 
 
[37] 
Alginate-HPMC Gatofloxacin Rabbit Eye irritation test (Draize test). Precorneal drainage 
assessment by gamma scintigraphy. 
 
No sign of ocular irritation. AUC(0-10h) values were found 3.58-fold higher for 
in situ gel compared with standard eye drop.  
[38] 
Alginate-NaCMC Gatifloxain 
 
Rabbit Eye irritation test (Draize test). Assessment of 
antimicrobial efficacy on a S. aureus infection 
model by clinical symptoms scoring. 
 
No sign of ocular irritation. Significant improvement in the observed symptoms 
for in situ gel compared with marketed solution. 
[36] 
Alginate-Gellan 
gum 
Matrine Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by HPLC. 
AUC(0-30) values were found 4.65-fold, 3.44-fold and 2.83-fold higher for 
alginate-gellan gum, alginate and gellan gum in situ gels respectively, compared 
to standard drug solution. 
 
[39] 
Multi-stimuli responsive gelling systems 
 
Alginate-
Poloxamer® 
 
Pilocarpine 
 
Rabbit 
 
Assessment of pupil diameter. 
 
AUC(0-360h) values were found 4.38-fold, 2.85-fold and 1.36-fold higher for 
alginate-poloxamer, poloxamer and alginate in situ gels, respectively, compared 
with standard solution. 
 
 
[40] 
Carbomer®-
xanthan gum 
Ofloxacin Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by HPLC.  
No sign of ocular irritation. In situ gel and Oflox® showed significant difference 
in residence time at all point intervals. 
 
[41] 
Alginate-chitosan Levofloxacin Rabbit Eye inflammation with infra-red camera. Precorneal 
drainage assessment by gamma scintigraphy. 
Standard eye drop cleared more rapidly from the corneal region and reached 
systemic circulation via nasolacrimal drainage, compared with in situ gel. 
 
[42] 
Chitosan-
PNIPAAm 
Timolol Rabbit Measurement of intraocular pressure by Schiotz 
tonometer. 
At all time points, in situ gels exhibited stronger IOP lowering effect compared 
with standard solution. Maximum IOP decrease was found higher for in situ gel 
(3.375 kPa) compared with standard solution (2.395 kPa).  
[43] 
Abbreviations: AUC = Area under the curve; EB = Evans blue; HA = Hyaluronic acid; HCl = Hydrochloric acid; HEC = 
Hydroxyethyl cellulose; HET-CAM = Hen's egg-chorioallantoic membrane test; HPLC = High performance liquid chromatography; 
HPMC = Hydroxypropyl methyl cellulose; IOP = Intraocular pressure; NaCMC = Sodium carboxymethycellulose; PET = Positron 
emission tomography; pNIPAAm = Poly(N-isopropylacrylamide); ΔIOP = Intraocular pressure variation
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2.1. Thermo-responsive gelling systems.  
Thermo-responsive materials have been the first type of stimuli-responsive materials used for the 
development of in situ gels. They have been investigated for many biomedical applications [44]. 
These materials undergo a sol-gel transition above a certain temperature called the lower critical 
solution temperature (LCST). The gelation is usually due to an increase in hydrophobicity by the 
formation of intermolecular hydrogen bonding, hydrophobic interactions and physical 
entanglements of polymer chains [45,46]. The temperature of the human ocular surface is around 
33.7°C in normal subjects [47,48]. Some thermo-responsive materials exhibit a LCST around the 
eye temperature, making them suitable for the development of in situ gels for ocular drug 
delivery.  Among them, Poloxamers®, poly(N-isopropylacrylamide) (PNIPAAm), xyloglucan 
and glycerol-2-phosphate showed promising results in vivo. 
2.1.1. Poloxamer®-based gelling systems 
Poloxamers
®
, also known by the trade name Pluronic
®
, are synthetic, nonionic and amphiphilic 
polymers composed of a hydrophobic block of poly(propylene oxide) (PPO) flanked by two 
hydrophilic blocks of poly(ethylene oxide) (PEO), poly(ethylene oxide)- poly(propylene oxide)-
poly(ethylene oxide) (PEO-PPO-PEO). Poloxamers® 188 and 407 are both approved by the 
Food and Drug Administration (FDA) utilized in various cosmetic, industrial and pharmaceutical 
applications. Since 1970’s, these polymers have been used as inactive ingredients of numerous 
marketed eye drops due to their excellent biocompatibility, non-toxicity, biodegradability and 
surfactant properties. When dispersed in aqueous solution at low concentration, Poloxamers
®
 
form colloidal formulations that reduce surface tension and thus increase drug permeation [49]. 
At concentrations above 15% (w/w), poloxamers® are liquid at cold (~4°C) or room (~20C) 
temperature and form a colorless and transparent gel at the temperature of the eye (~32°C) [50].  
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In an in vivo rabbit model, poloxamer-based in situ gels showed a significantly higher absorption 
to the aqueous humor of loteprednol [19], methazolamide [20] and timolol [21], compared to 
standard formulations. However, it has been shown that the delivery of methazolamide and 
timolol, both anti-glaucoma drugs, did not significantly reduce the intraocular pressure (IOP) 
compared with standard formulations [20,21]. Besides its excellent biocompatibility, 
poloxamers® exhibited low mechanical strength and rapid erosion. This intrinsic instability is 
due to the weak hydrophobic interactions between the PPO blocks [51].  
 Precorneal retention time increases with poloxamer
®
 concentration but the high concentration 
necessary to formulate in situ gels can cause ocular irritation [49]. Thereby, viscosifiers have 
been added to poloxamer® in order to reduce its concentration without modifying the gelling 
properties. Cellulose is a natural polysaccharide and represents the most abundant polymer on 
earth. Many of its derivatives, such as ethylcellulose (EC), methylcellulose (MC), hypromellose 
(INN, also called hydroxypropyl methyl cellulose (HPMC)) or hydroxyethyl cellulose (HEC), 
are currently used as viscosifiers in numerous commercialized eye drops to increase their 
viscosity. It has been shown that the addition of HPMC or HEC to poloxamer-based in situ gels 
significantly increased its mucoadhesive properties and the release of ciprofloxacin, allowing an 
enhanced antimicrobial effect compared to commercial formulations [22]. 
2.1.2. PNIPAAm-based gelling systems 
Poly(N-isopropylacrylamide) (PNIPAAm) is a synthetic polymer that can undergo a reversible 
thermo-sensitive coil-globule transition in aqueous solutions at approximatively 33°C [52] (Fig. 
2). Below this temperature, PNIPAAm is water-soluble and hydrophilic, and above this 
temperature, it is able to form inter- and intrachain associations resulting in an insoluble and 
hydrophobic aggregate [53]. Compared to the other polymers used for in situ gels, PNIPAAm is 
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not FDA-approved. A PNIPAAm-based in situ gel has been tested to deliver epinephrine in an in 
vivo rabbit model. Results have demonstrated that the IOP-lowering effect was 4-fold longer 
compared to standard eye drops [23]. However, PNIPAAm is not biodegradable, limiting its use 
for eye drop formulations [54]. Thereby, PNIPAAm has been grafted to natural polymers in 
order to obtain a safe and biodegradable in situ gels.  
Hyaluronic acid (HA), also named hyaluronan, is a glycosaminoglycan composed of repeating 
disaccharide units of D-glucuronic acid and N-acetyl glucosamine which are negatively charged 
at physiologic conditions [55].  It represents another natural polymer particularly used in the 
field of ophthalmology due to its excellent biocompatibility and biodegradability. Naturally 
biocompatible and biodegradable, HA is a component of vitreous and aqueous humor and can be 
degraded by hyaluronases present in ocular tissues. In some studies, PNIPAAm has been grafted 
to HA to develop in situ forming gels for the delivery of ketaconazole [24] and cyclosporin A 
[25] to the anterior segment of ocular tissue. Results showed that the use of PNIPAAm-HA gel 
improved precorneal retention time and thus increased drug levels on the cornea, compared with 
marketed eye drops [25]. Moreover, a significantly higher cure rate of Candida albicans 
infections was observed after delivery of ketaconazole loaded in PNIPAAm-HA in situ gel, 
compared with marketed solution [24]. Also, studies showed no sign of ocular irritation after 
instillation [24,25]. Compared to other thermo-responsive polymers, PNIPAAm has a highly 
efficient sol-gel transition independently of the concentration and the molecular weight used. 
However, PNIPAAm is not transparent after sol-gel transition, and therefore, can alter vision of 
the patient. 
2.1.3. Xyloglucan-based gelling systems 
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Xyloglucan is a highly soluble natural polysaccharide derived from tamarind seeds. When 
partially degraded by β-galactosidase, this polymer exhibits thermo-responsive properties [56]. 
The temperature of the sol-gel transition and the degradation rate can be modulated by varying 
the polymer concentration [57].  
Xyloglucan-based in situ gels were assessed for ocular delivery of pilocarpine, a drug used to 
enlarge the pupil (miotic response). Results showed that the in situ gel had a greater effect on the 
miotic response compared to standard pilocarpine formulations. Moreover, similar effects on the 
miotic response have been observed between xyloglucan-based in situ gel at a concentration of 
1.5 wt% and a Poloxamer®-based gel at a concentration of 25 wt% [26] (Fig. 3). 
2.1.4. Glycerol phosphate-based gelling systems 
Recently, glycerol phosphate has been used to modify the thermo-responsive properties of 
natural polymers, including chitosan and gelatin. For this process, glycerol phosphate interacts 
with protonated amines of polymers, inducing higher solubility at low temperatures [58].  
Several researchers have successfully developed chitosan-gelatin-glycerol 2-phosphate in situ 
gels, with a sol-gel transition at body temperature. These formulations were assessed for the 
delivery of levocetirizine [27], timolol [28] and latanoprost [29].  Precorneal retention of 
levocetirizine and antiallergic conjunctivitis efficacy were found higher for in situ gels compared 
with aqueous solutions [27]. For the delivery of timolol, precorneal retention has been shown to 
be around 10 min for standard eye drops and at least 60 min for the in situ gel. Moreover, IOP 
lowering effect lasted 12h and 24h for standard eye drops and the in situ gel, respectively [28].  
Finally, it has been found that the delivery of latanoprost was more efficient for the in situ gel 
compared with Xalatan
®
, a marketed formulation. Interestingly, IOP measurement showed that a 
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weekly administration of the in situ gel showed a similar IOP lowering effect pattern when 
compared with daily administration of Xalatan
® 
[29] (Fig. 3). This result confirmed that 
chitosan-gelatin-glycerol 2-phosphate in situ gels represent a promising DDS by remarkably 
reducing repetitive instillations and thus increasing the patient compliance for glaucoma 
treatment.  
2.2.pH-responsive gelling systems 
The pH of the ocular surface is neutral. Some pH-responsive materials have the property to be 
liquid at an acidic pH and undergo the sol-gel transition when the pH increases. Carbopol
®
 and 
chitosan are both pH-responsive materials that have been extensively used for the development 
of in situ gels for ocular drug delivery. 
2.2.1. Carbopol®-based gelling systems 
Carbopol
®
, also known by the generic name Carbomer
®
, is a synthetic polymer derived from 
cross-linking of poly(acrylic acid). A high purity grade version of this polymer, Carbopol® 
934P, was designed for the pharmaceutical industry in the 1960’s by Lubrizol (Wickliffe, OH) 
and have been used in many commercial ophthalmic gels and ointments. Carbopol
®
 is a pH-
sensitive polymer that is in a liquid form at a pH lower than 5.5, and is able to form a semi-solid 
gel above this pH. The sol-gel transition occurs with the formation of a three dimensional (3D) 
network swollen in aqueous solution due to electrostatic repulsion and osmotic forces within the 
polymer backbone [59] (Fig. 2). Due to its synthetic nature, physical and chemical properties of 
Carbopol
®
 can be fine-tuned to make it suitable for various biomedical applications. However, 
high concentration of Carbopol
®
 is required to formulate in situ gels and its acidic nature can be 
toxic for the eye. To reduce Carbopol
®
 concentration without compromising the gelation 
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efficiency, cellulose derivatives such as HPMC have been added into the formulation [30]. 
Carbopol
®
-HPMC in situ gels have been developed to deliver puerarin [30], baicalin [31], 
pefloxacin [32] and timolol and brimonidine simultaneously [33]. Compared to standard 
solutions, higher drug concentrations were delivered in ocular tissues by these in situ gels, 
showing their ability to increase precorneal retention time [30,31]. It has also been shown that 
after instillation, the pefloxacin concentration was found above the minimum inhibitory 
concentration for 24h for in situ gels, whereas it was only 12h for commercial eye drops [32]. 
Moreover, the simultaneous delivery of two anti-glaucoma drugs, timolol and brimonidine, by 
the Carbopol
®
-HPMC in situ gel allowed a sustained and higher IOP-lowering effect compared 
to COMBIGEN
®
 [33]. Finally, Carbopol
®
-HPMC in situ gels showed no sign of ocular irritation 
after instillation [33].  
2.2.2.  Chitosan-based gelling systems 
Chitosan is a linear amino polysaccharide derived from chitin, the main component of shells of 
crustaceans, insects and microorganisms, representing the second most abundant natural polymer 
on earth after cellulose. Chitosan can be solubilized in aqueous solutions only in acidic 
environments. When the pH exceeds 6.2, chitosan is neutralized and forms a gel. This property 
allows chitosan to form a gel at immediate contact with the cornea, where the pH is neutral. The 
combination of Carbopol
®
 and chitosan have been used to form an in situ gel for the delivery of 
timolol. Results demonstrated an increased and more sustained IOP-lowering effect for the 
formulated in situ gel compared with GLUCOMOL
®
 [34]. However, the low purity and batch-to-
batch reproducibility of chitosan considerably limits its application into market compared to 
other synthetic polymers such as Carbopol
®
. Moreover, the use of pH-responsive materials for 
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ocular application requires the instillation of acidic formulations on the ocular surface which can 
induce discomfort and lacrimation for the patient [60].  
2.3.Ion-responsive gelling systems 
The human tear fluid is composed of different mono or divalent cations, particularly Na
+
, Mg
+
 
and Ca
2+
. The sol-gel transition of ion-responsive materials occurs in the presence of cations that 
generate ionic bonds within the polymer backbone, creating an ‘egg box’ structure [61]. Among 
these ionic materials, gellan, xanthan gum and alginate have been widely used to develop in situ 
gels for ocular drug delivery.  
2.3.1. Gellan and xanthan gum-based gelling systems 
Gellan gum (also known by the trade name Gelrite
®
) and xanthan gum are both naturally derived 
anionic polymers produced by the bacterium Sphingomonas elodea and Xanthomonas 
campestris, respectively. Gellan gum is an anionic linear polysaccharide composed of repeating 
units of tetrasacharide composed of two units D-glucose, one of D-glucuronic acid and L-
rhamnose, while xanthan gum is composed of pentasaccharide repeating units of mannose, 
glucose and glucuronic acid.  These polymers can be stored in a liquid state and form a gel upon 
contact of the eye due to the presence of cations in the tear film. The sol-gel transition occurs by 
the formation of ionic bonds of the polymer backbone. Gellan and xanthan gum are already used 
in clinic as in situ gels, such as TIMOLOL MALEATE EX
®
 (Timolol 0.25%, Sandoz Inc., 
Switzerland), TIMOPTIC-XE
®
 (Timolol 0.25%, Valeant Pharms LLC, USA), TIMOLOL L.P.
®
 
(Timolol 0.25% and 0.5%, Santen Oy, Japan) and MOXEZA
®
 (Moxifloxacin 0.5%, Novartis 
Pharms Corp, Switzerland). On an in vivo rabbit model, gellan gum was used to deliver 
moxifloxacin [35] and brinzolamide [18].  It was shown that the gellan gum-based in situ gel 
could deliver a 6-fold higher concentration of moxifloxacin in the aqueous humor compared to 
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VIGOMOX
®
, as control [35]. Moreover, the delivery of brinzolamide by the developed in situ 
gel prolonged the IOP lowering effect compared to standard solutions [18]. Gellan gum has also 
been combined with K-carrageenan to formulate an in situ gel for the delivery of econazole. 
Results showed higher precorneal retention of the drug compared to standard solutions [37].  
 
2.3.2. Alginate-based in situ gelling systems  
Alginate is a natural, anionic, hydrophilic polysaccharide isolated from brown seaweed. It is 
composed of β-D-mannuronic acid linked to R-L-guluronic acid units. Sodium alginate can 
interact with cations such as Ca
2+
 present in the tear film to form a gel upon contact with the 
cornea. Alginate is already used in clinic in different ophthalmic formulations such as 
MIKELAN LA
®
 (Carteolol hydrochloride 1% or 2%, Otsuka Pharm Co., Ltd, Japan), 
MIKELUNA
®
 (Carteolol hydrochloride 1%, Latanoprost 0.005%, Otsuka Pharm Co., Ltd, 
Japan), CARTEOL L.P. (Carteol 1% or 2%, Chauvin Laboratory, France). Alginate-based in situ 
gel was also used with cellulose HMPC as viscosifiers for the delivery of gatifloxacin, and 
showed better precorneal retention time than HMPC or alginate solutions alone [38]. Sodium 
alginate and gellan gum were also used with sodium carboxymethycellulose (NaCMC) to deliver 
gatifloxacin against induced bacterial keratitis on an infected rabbit model in vivo. It has been 
found that the in situ gel was more effective in the treatment of keratitis (redness, lacrimal 
secretion, mucoid discharge, response to ocular stimulus and swelling of eyelids) compared to 
conventional eye drops [36]. Interestingly, a mixture of gellan gum and alginate was used to 
form an in situ gel and showed a greater ability to retain the drug on the corneal surface than 
gellan gum or alginate in situ gel alone [39]. These results suggest that the combination of ion-
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sensitive polymers can improve the gelation properties, allowing increased precorneal retention 
of drugs on the corneal surface. 
2.4.Multi-stimuli responsive gelling systems 
In order to increase strength and gelation properties of gelling systems, combinations of different 
stimuli-responsive materials have been tested. For example, thermosensitive poloxamer
®
 and 
ion-sensitive alginate were combined to formulate composite in situ gel for the delivery of 
pilocarpine to the anterior segment [40]. Drug release and pupil constriction were found to be 
higher for poloxamer
®
-alginate in situ gels compared with poloxamer or alginate gels alone (Fig. 
3A-B). In another study, an in situ gel based on ion-sensitive xanthan gum and pH-sensitive 
Carbopol
®
 has been formulated for the delivery of ofloxacin. Results demonstrated a significant 
increase in retention time with optimized concentrations of both polymers, compared with 
OCUFLOX
®
, a marketed ointment [41]. pH-sensitive chitosan was also combined with alginate 
to develop an in situ gel for sustained release of levofloxacin to the anterior segment. This 
formulation showed better therapeutic efficacy compared to standard eye drops [42]. 
Finally, a combination of chitosan with thermosensitive PNIPAAm was developed and assessed 
for the delivery of timolol maleate. [43]. In vivo studies demonstrated that drug release was 
higher and longer for this in situ gel compared with conventional eye drops (Fig. 3C). Moreover, 
the formulation had a higher IOP-lowering effect at all time points compared with the standard 
eye drops (Fig. 3D). All these studies prove that the development of multi stimuli-responsive 
materials improved gelation properties of in situ gels, providing higher precorneal drug retention 
on the ocular surface. 
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Fig. 3. Sustained drug release and improved therapeutic effect by using in situ gels 
compared with conventional eye drops. (A) Cumulative amount of pilocarpine released as a 
function of time from various pilocarpine-containing solutions. All measurements were 
performed in triplicate, and the standard deviations were all within 3% (From [40]). (B) Decrease 
in pupil diameter vs time profiles for various pilocarpine-containing solutions. All the 
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measurements were performed in triplicate (From [40]). (C) Thermosensitive PNIPAAm–CS 
synthesis outline. (D) Morphology change of the PNIPAAm–CS gel forming solution below and 
upon LCST by using an optical microscope. Scale bar, 20 μm. (E) Timolol maleate concentration 
in aqueous humor after instillation of 0.5% timolol maleate conventional and thermosensitive 
PNIPAAm–CS gel forming solution (n=5) (From [43]). (F) The IOP-lowering effect of timolol 
maleate in thermosensitive PNIPAAm–CS and conventional eye drop (n=4) (From [43]). 
3. Nanoparticle-based drug delivery systems 
One of the reasons for the low bioavailability of drugs after topical administration is the short 
retention time due to the rapid clearance of the ocular surface via tear film renewal, nasolacrimal 
drainage and biologic and enzymatic drug degradation. Therefore, microparticle- and 
nanoparticle-based systems have been used to increase the retention time of drugs on the ocular 
surface. Due to their functional groups and the surface charge, microparticles and nanoparticles 
(NPs) can closely interact with the mucin layer of the ocular surface to prolong the presence of 
drugs on the cornea [62]. Also, the encapsulation of drugs into NPs protects them from 
enzymatic degradation; thus, a lower concentration of drugs is required to reach the therapeutic 
effect, preventing side effects. Numerous lipidic and polymeric materials and/or a combination 
of them have been used to develop NPs that are able to deliver a variety of drugs to the anterior 
segment (Table 2). 
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Table 2. Nanoparticles-based systems used for ophthalmic drug delivery. 
 
 
Drug model Animal 
model 
 
In vivo studies In vivo results Ref 
 
Natural materials 
 
Chitosan 
 
Ganciclovir 
 
Rat 
 
Determination of drug concentration in aqueous 
humor by HPLC. 
 
AUC(0-∞) and Cmax values were found to be 4.69-fold and 2.7-fold higher, 
respectively, for NPs solution compared with aqueous solution. 
 
 
[63] 
 Diclofenac Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in aqueous humor by HPLC. 
No sign of ocular irritation. AUC(0-720min) values were found to be 2.46-fold higher 
for NPs solution compared with commercial eye drops. Cmax was found to be similar 
for NPs solution and commercial eye drops. 
 
[64] 
 Cyclosporine A Sheep Determination of drug concentration in aqueous 
and vitreous humor by HPLC. 
After 2h, drug concentration was found to be 40.70±1.0 and 35.60±2.50 ng/mL in 
aqueous and vitreous humors, respectively. After 72h, drug concentration was found to 
be 41.70±0.90 and 36.70±0.30 ng/mL in aqueous and vitreous humors, respectively. 
 
[65] 
 Cyclosporine A Rabbit Determination of drug concentration in ocular 
tissues by liquid scintillation counting. 
 
Corneal and conjunctival drug levels were found 2- fold to 6-fold higher for NPs 
solution compared with standard aqueous solution.  
[66] 
 Indomethacin Rabbit Determination of drug concentration in aqueous 
humor by HPLC. 
AUC and Cmax values were found 17-fold and 13-fold higher, respectively, for NPs 
solution compared with standard solution. 
 
[67] 
 Celocoxib Rat Determination of drug concentration in ocular 
tissues by HPLC. 
AUC(0-24), AUC(0-∞) and Cmax values were found 4.8-fold to 27.7-fold higher for 
NPs solution compared with standard solution.  
 
[68] 
 Timolol Rabbit Precorneal retention by fluorescence imaging. 
Measurement of intraocular pressure. 
After 1.5h, higher precorneal retention for NPs solution compared with standard eye 
drops. Maximal IOP lowering effect was observed at 4h with a value of 10.5±0.51 
mmHg for NPs solution. Maximal IOP lowering effect was observed at 3h with a value 
of 6.8±0.35 mmHg for standard eye drops. 
[69] 
 Carteolol Rabbit Precorneal retention by gamma scintigraphy. 
Measurement of intraocular pressure by a Schiotz 
tonometer. 
Standard solution showed a quick fall in radioactive counts on corneal surface with 
respect of time as compared to NPs suspension in 0.5h. Maximum IOP lowering effect 
was observed at 2h with a value of 18.04±0.697 mmHg for NPs solution. Maximum 
IOP lowering effect was observed at 1h with a value of 22.616±0.639 mmHg for NPs 
solution. 
 
[70] 
Alginate-
chitosan 
Azelastine Rat Determination of drug efficacy by counting of 
scratching instances, by analysis of conjunctival 
hyperemia, edema and by eosinophil count. 
 
Similar reduction in eye scratching behavior for NPs solution and Azelast®. Higher 
reduction of hyperemia and edema for NPs solution compared with Azelast®. 
Reduction of eosinophil count lasted 4h for Azelast® and 10h for NPs solution. 
 
[71] 
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 5-Flourouracil Rabbit Determination of drug concentration in ocular 
tissues by HPLC. 
AUC(0-8) and Cmax values were found 17-fold and 13-fold higher, respectively, for 
NPs solution compared with standard solution. 
 
[72] 
Albumin Pilocarpine Rabbit Measurement of intraocular pressure by a Schiotz 
tonometer. 
AUC values were found to be 3.19-fold and 1.67-fold higher for 1%-drug NPs solution 
compared with 1%-drug and 4%- drug standard solution, respectively. 
 
[73] 
Albumin-
chitosan 
Tetracaine Rabbit Determination of blink response after cotton swab 
stimuli. 
No statistical difference of efficacy between NPs solution and standard solution. 
Duration of action was 4-fold higher for NPs solution compared with standard solution. 
 
[74] 
 Atropine Rabbit Measurement of mydriasis by video recording and 
analysis. 
AUC values were found to be at 10.67 for 0.66%-drug NPs solution and 10.02 for 1%-
drug standard solution. Maximum effect (pupil-corneal ratio) was found to be at 0.630 
for 0.66%-drug NPs solution and at 0.596 for 1%-drug standard solution. 
 
[75] 
Gelatin Timolol Rabbit Eye irritation test (Draize test).  Measurement of 
intraocular pressure by a plunger load tonometer. 
 
No sign of ocular irritation. AUC values were found to be 2.27-fold higher for NPs 
solutions compared with marketed eye drops. 
[76] 
 Moxifloxacin Rabbit Eye irritation test. Assessment of antimicrobial 
efficacy by observation of clinical parameters. 
No sign of ocular irritation. No difference in antimicrobial efficacy between NPs 
solution at a dose regime of twice a day and MOXIGRAM® at a dose regime of four 
times a day. NPs solution decreased secretion (discharge), redness and swelling faster 
when compared with MOXIGRAM®. 
 
[77] 
HA-chitosan Dexamethasone Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in aqueous humor by HPLC. 
No sign of ocular irritation. AUC(0-∞) values were found to be 1.93-fold and 2.39-fold 
higher for chitosan NPs solution and chitosan-HA NPs solution, respectively, 
compared with standard solution. 
 
[78] 
 Dorzolamide or 
Timolol 
Rabbit Eye irritation test (Draize test). Measurement of 
intraocular pressure by a Schiotz tonometer. 
No sign of ocular irritation. IOP lowering effect peaked at 3h for marketed solution, at 
4h and observed for up to 8h for chitosan NPs solution, and at 4h and observed for up 
to 12 h for chitosan-HA NPs solution. 
 
[79] 
EC Acetazolamide Rabbit 
 
Measurement of intraocular pressure by a 
tonometer. 
 
Maximum IOP reduction was found 1.33-fold higher for NPs solution compared with 
standard solution. Mean time for IOP reducing effect was 6h for NPs solution and 5h 
for standard solution.  
[80] 
Synthetic materials 
 
Eudragit® 
 
Aceclofenac 
 
Rabbit 
 
Assessment of anti-inflammatory efficacy by 
observation of polymorphonuclear leucocyte 
(PMN) migration and lid closure. 
 
 
PMN count in tears were found to be 1.57-fold and 1.18-fold lower for NPs solution 
and standard aqueous solution, respectively, compared with control eyes.  
 
[81] 
 Aceclofenac Rabbit Assessment of anti-inflammatory efficacy by 
assessment of polymorphonuclear leucocyte 
(PMN) migration and lid closure. 
 
PMN count in tears at 3h were found to be 1.66-fold and 1.28-fold lower for NPs 
solution and standard aqueous solution, respectively, compared with control eyes. 
[82] 
 Diclofenac Rabbit Assessment of anti-inflammatory efficacy by Greater decrease of PMN count at all time points for NPs solution compared with [83] 
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assessment of polymorphonuclear leucocyte 
(PMN) migration and lid closure. 
 
standard aqueous solution. 
 Ibuprofen Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in ocular tissues by HPLC. 
 
No sign of ocular irritation. 2h after instillation, drug concentrations were 1.54±0.06 
µg/mL for NPs solution and 0.93±0.08 µg/mL for standard solution. 
[84] 
 Betaxolol Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by HPLC. 
Measurement of intraocular pressure by an 
indentation tonometer. 
NPs solution was found safer and less toxic than standard solution. Higher drug 
concentrations were found at all time points for NPs solution compared with standard 
solution. After 90 min, drug concentrations cannot be detected for standard solution, 
whereas drug concentrations were detected until 240 min for NPs solution. For 
standard solution, maximum IOP lowering effect was found at 30 min (5.04 mmHg) 
and the effect significantly declined after 60 min. For NPs solution, maximum IOP 
lowering effect was found at 120 min (4.89 mmHg). 
 
[85] 
 Acetozalamide Rabbit Measurement of intraocular pressure by a Riester 
tonometer. 
For standard solution, maximal IOP lowering effect was observed at 2h with a ΔIOP 
value of 2.98±0.11 mmHg. After 6h, no IOP lowering effect was observed. For NPs 
solution, maximal IOP lowering effect was observed at 8h with a ΔIOP value of 
5.32±0.07 mmHg. 
 
[86] 
 Brimonidine Rabbit Eye irritation test (Draize test). Measurement of 
intraocular pressure by a Schiotz tonometer. 
 
No sign of ocular irritation. AUC(ΔIOP vs. t) values were found to be 3.55-6.98-fold higher 
for NPs solution, compared with IOBRIM®. 
[87] 
 Amphoterin B Rabbit Eye irritation test (Draize test). No sign of ocular irritation. 
 
[88] 
 Azelastine Rat Assessment of eye scratching, hyperemia, edema 
and eosinophils in the conjunctiva. 
No significant difference of eye scratching, hyperemia and edema between NPs 
solution and AZELAST®. Eosinophil counts were found lower at 6h and 10h for NPs 
solution compared with AZELAST®. 
 
[89] 
 Acetazolamide Rabbit 
 
Measurement of intraocular pressure by a 
tonometer. 
 
Maximum IOP reduction was found 1.51-fold higher for NPs solution compared with 
standard solution. 
[80] 
PLA-
Dextran-
PBA 
 
Cyclosporine A Mice Quantification of tear fluid production and 
fluorescein staining analysis after dry eye disease 
induction. Histopathology analysis. 
Similar tear fluid production and fluorescein staining were observed for NPs instilled 
once a week compared with the conventional treatment (RESTASIS®) instilled three 
times a day. No sign of ocular irritation.  
[90] 
PLA-PMA-
PBA 
 
Cyclosporine A Rat Slit lamp and OCT imaging examination. No sign of ocular toxicity. [91] 
PLGA Fluoromethalone Pig Eye irritation test (Draize test). Assessment of 
anti-inflammatory efficacy by scoring of clinical 
symptoms. Determination of drug concentration in 
ocular tissues by HPLC. 
 
No sign of ocular irritation. Ocular inflammation was found significantly lower for 
NPs solution compared with ISOPTOFLUCON®.  
 
[92] 
 Aceclofenac Rabbit Assessment of anti-inflammatory efficacy by PMN counts were found significantly lower for MPs solution, compared with standard [93] 
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observation of polymorphonuclear leucocyte 
(PMN) migration and lid closure. 
 
aqueous solution. 
PLGA-PEG Dorzolamide Rabbit Measurement of intraocular pressure by a 
tonometer. 
 
Similar efficacy on IOP lowering between one drop of NPs and 4 drops of 
TRUSOPT®.  
[94] 
PCL Cyclosporine A Rabbit Determination of drug concentration in tear fluid 
by liquid scintillation counting. 
 
AUC values were significantly higher for NPs solution compared with oily control. [95] 
 Indomethacin Rabbit Determination of drug concentration in tear fluid 
by liquid scintillation counting. 
AUC(0-4h) and Cmax values were found to be 4-fold and 7-fold higher, respectively, for 
NPs solution compared with standard INDOCOLLYRE®. 
 
[96] 
Combination of natural and synthetic materials 
 
Chitosan-
PLGA 
 
Forskalin 
 
Rabbit 
 
Eye irritation test (infra-red camera). Assessment 
of precorneal retention by gamma scintigraphy. 
Measurement of intraocular pressure by a Schiotz 
tonometer. 
 
 
No sign of ocular irritation. Precorneal retention was found significantly higher for 
NPs solution compared with standard solution. For standard solution, maximum IOP 
lowering effect was found at 1h (20.1±1.56 mmHg). For NPs solution, maximum IOP 
lowering effect was found at 8h (16.3±0.75 mmHg). 
 
[97] 
 Fluocinolone Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by HPLC. 
No sign of ocular irritation. AUC(0-∞) and Cmax values were found to be 5.23-fold and 
2.19-fold higher, respectively, for chitosan-PLGA NPs solution compared with PLGA 
NPs solution. 
 
[98] 
Chitosan-
PLA 
Amphotericin B Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by HPLC. 
Assessment of corneal permeation by fluorescein 
staining. 
 
No sign of ocular irritation. AUC values were found 1.5-fold higher for NPs solution 
compared with standard solution. Higher permeation and retention effects were noted 
for NPs solution compared with fluorescein solution. 
[99] 
Chitosan-
PEG 
Resveratrol Rabbit  Assessment of corneal permeation by fluorescein 
staining. Measurement of intraocular pressure by a 
tonometer. 
Increased fluorescent signal at the inner site of the cornea for chitosan-PEG NPs 
solution compared to chitosan NPs. Chitosan-PEG NPs solution reduced IOP by 
4.3±0.5 mmHg up to 8h. 
[100] 
 Resveratrol and 
quercetin 
 
Rabbit Measurement of intraocular pressure by a 
tonometer. 
Chitosan-PEG NPs solution reduced IOP by 5.5±0.5 mmHg up to 8h. [101] 
Chitosan-
PEG-PCL 
Diclofenac Rabbit Eye irritation test (Draize test).  Assessment of 
corneal permeation by Nile red staining. 
Determination of drug concentration in aqueous 
humor by HPLC. 
 
No sign of ocular irritation. AUC(0-24h) and Cmax values were found 2.3-fold and 
2.11-fold higher, respectively, for NPs solution compared with commercial eye drops. 
[102] 
Eduragit®-
HA 
 
Gatifloxacin and 
prednisolone 
Rabbit Determination of drug concentration in aqueous 
humor by HPLC. 
AUC(0-24h) and Cmax values were found 1.77-fold and 1-76-fold higher, respectively, 
for NPs solution compared with commercial eye drops. 
 
[103] 
Combination of polymers with lipidic vectors 
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Chitosan 
 
Methazolamide 
 
Rabbit 
 
Eye irritation test (Draize test). Measurement of 
intraocular pressure by a tonometer.   
 
No sign of ocular irritation. AUC(0-8h) values were 237.8 mmHg for chitosan lipid 
NPs, 175.2 mmHg for Azopt®, 81.2 mmHg for lipid NPs and 49.9 mmHg for standard 
solution. 
 
 
[104] 
 Dexamethasone Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in aqueous humor by HPLC. 
 
AUC(0-24h) and Cmax values were found 5.38-fold and 2.37-fold higher, respectively, 
for NPs solution compared with commercial eye drops. 
 
[105] 
 Timolol Rabbit Eye irritation test. Assessment of precorneal 
retention by gamma scintigraphy. Determination 
of drug concentration in tear fluid by HPLC. 
Measurement of intraocular pressure by a 
tonometer.   
No sign of ocular irritation. Higher precorneal retention of chitosan-coated liposomes 
compared with standard eye drops and liposomes. AUC(0-∞) and Cmax values were 
found 1.72-fold and 2.67-fold higher, respectively, for chitosan-coated liposomes 
compared with uncoated liposomes. Maximum IOP was 19.67±1.11 mmHg for 
chitosan-coated liposomes and 23.80 ± 1.72 mmHg for standard eye drops. 
 
[106] 
 Amphotericin B Rabbit Eye irritation test (symptom scoring). 
Determination of drug concentration in tear fluid 
and aqueous humor by HPLC. 
 
No sign of ocular irritation. Chitosan-lipid carriers had a significantly greater 
percentage activity remaining in the pre-corneal area after 30 min (71.7%) as compared 
with lipid carriers (54.1%) and standard eye drops (40.8%). AUC(0-∞) and Cmax values 
were found 1.99-fold and 1.27-fold higher, respectively, for chitosan lipid carriers 
compared with lipid carriers. 
 
[107] 
 Amphotericin B Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by mass 
spectrophotometry. 
 
No sign of ocular irritation. AUC(0-∞) values were found 2.05-fold higher, for 
chitosan/lecithin NPs compared with Fungizone®. 
[108] 
 Flurbiprofen Rabbit Eye irritation test (symptom scoring). Assessment 
of precorneal retention by gamma scintigraphy. 
No sign of ocular irritation. AUC(0-10min) values for chitosan-coated liposomes were 
found to be 2.84-fold and 1.53-fold higher in the cornea-conjunctiva region compared 
with standard eye drop and uncoated liposomes, respectively. 
 
[109] 
 Flurbiprofen Rabbit Eye irritation test (symptom scoring). Assessment 
of precorneal retention by gamma scintigraphy. 
No sign of ocular irritation. AUC(0-10min) values for chitosan-coated lipid carriers 
were found 4.66-fold and 1.70-fold higher in the cornea-conjunctiva region compared 
with standard eye drops and uncoated lipid carriers, respectively. 
  
[110] 
 Ofloxacin Rabbit  Eye irritation test (Draize test). Assessment of 
precorneal retention by fluorescein staining. 
Determination of drug concentration in aqueous 
humor by HPLC. Assessment of anti-microbial 
efficacy by keratitis induction and symptoms 
scoring. 
 
Precorneal retention time was observed during 40-60 min for chitosan lipid carriers 
and for 20-40 min for lipid carriers. Maximum drug concentration was found at 1h for 
commercial eye drops and at 4h for chitosan lipid carrier. After keratitis induction, 
significantly lower conjunctival redness and corneal opacity was observed with 
chitosan lipid nanocarrier treatment compared with commercial solution.  
[111] 
 Natamycin Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by mass 
spectrophotometry. 
 
No sign of ocular irritation. AUC(0-∞) values were found 1.47-fold higher, for 
chitosan/lecithin NPs compared with standard suspension. Clearance was significantly 
decreased (7.4-fold) for chitosan/lecithin NPs compared with standard suspension.  
 
[112] 
 Cyclosporin A Rabbit Determination of drug concentration in cornea, Higher drug absorptions in cornea, conjunctiva and sclera for chitosan-coated [113] 
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conjunctiva and sclera by HPLC. liposomes compared with liposomes. 
 
 Ciprofloxacin Rabbit Assessment of anti-microbial efficacy by bacterial 
conjunctivitis induction and symptoms scoring. 
 
No significant difference of antimicrobial efficacy between chitosan-coated liposomes 
and Ciloxan®. 
[114] 
Chitosan-
HA 
Moxifloxacin Rabbit 
 
Eye irritation test (Draize test). Determination of 
drug concentration in tear fluid by HPLC. 
 
No sign of ocular irritation. AUC(0-∞) and Cmax values were found 6.74-fold and 3.17-
fold higher, respectively for NPs solution compared with Vigamox®. 
 
[115] 
HA Tacrolimus Rabbit 
 
Determination of drug concentration in aqueous 
humor by HPLC. 
The relative bioavailability of HA-coated niosomes was 2.3-fold and 1.2-fold for that 
of suspension and non-coated niosomes, respectively. 
 
[116] 
 Doxorubicin Rabbit Determination of drug concentration in aqueous 
humor. Assessment of drug permeation in cornea 
by laser scanning microscopy.  
 
AUC and Cmax values were found 1.68-fold and 1.36-fold higher, respectively, for NPs 
solution compared with standard solution. Higher drug permeation was noted for NPs 
solution compared with standard solution. 
[117] 
PEG-PCL Diclofenac Rabbit Eye irritation test (Draize test). Determination of 
drug concentration in aqueous humor by HPLC. 
 
No sign of ocular irritation. AUC(0-24h) and Cmax values were found 2.02-fold and 
3.03-fold higher, respectively, for NPs solution compared with standard solution. 
[118] 
PEG-PLA Cyclosporin A Rabbit Determination of drug concentration in aqueous 
humor and cornea by HPLC. 
 
NPs solution exhibited 4.5-fold increase in retention effect on eyes compared with 
standard emulsions. 
[119] 
Abbreviations: AUC= Area under the curve; Cmax = Maximal concentration; EC= Ethyl cellulose; HA= Hyaluronic acid; HPLC = 
High performance liquid chromatography; IOP= Intraocular pressure; MPs= Microparticles; NPs= Nanoparticles; PCL= Poly(epsilon-
caprolactone); PEG= Polyethylene glycol; PLA= Polylactide; PBA = Phenylboronic; PMA = poly(methacrylic acid); PLGA= 
Poly(lactic-co-glycolic acid); PMN= Polymorphonuclear leucocyte ; ΔIOP= Intraocular pressure variation .Jou
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3.1.Polymeric nanoparticles 
Due to recent advances in the fields of biomaterials and nanotechnology, new types of polymeric 
DDS have been developed. Both natural and synthetic polymers have largely been used to 
formulate NP-based systems for ocular drug delivery [4].  
3.1.1. Naturally derived polymer-based nanoparticles  
Natural polymers are generally considered more biocompatible and mucoadhesive compared to 
synthetic polymers, making them suitable for the formulation of NPs for ocular DDS. Among 
them, chitosan, alginate, albumin, gelatin and hyaluronic acid (HA) have shown promising in 
vivo results as NP-based DDS. 
Chitosan. As we described in section 1.2, chitosan has been used as an ingredient for in situ gel 
forming formulation, due to its ability to increase its viscosity at body pH. Its high 
mucoadhesiveness and permeability make chitosan an attractive candidate for the formulation of 
NPs for ocular DDS. The mucoadhesive nature of chitosan is mediated via electrostatic 
interactions, hydrogen bonds, and hydrophobic effects [120]. Chitosan is also considered as a 
paracellular permeability enhancer due to its ability to reversibly open the tight junctions 
between epithelial cells [121]. During the last decades, chitosan has been used widely to develop 
NPs-based DDS for the anterior segment. It showed promising results in the delivery of a variety 
of drugs, such as anti-inflammatory drugs (ganciclovir [63], diclofenac [64], cyclosporine A 
[65,66], indomethacin [67] and celocoxib [68]) and anti-glaucoma drugs (timolol [69] and 
carteolol [70]). A recent study compared the stability and pharmacokinetics of different types of 
polymer as nanocarriers to deliver celecoxib: chitosan, alginate and other synthetic polymers 
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such as PCL, PLA and PLGA. Results demonstrated that chitosan NPs had the best in vitro 
stability and in vivo bioavailability in a rat model [68].  
Alginate. With its high molecular weight, alginate has mucoadhesive properties and thus 
represents a promising material to be used in ocular DDS. However, alginate has low stability 
and fast biodegradation, limiting its use for sustained drug release. Thereby, alginate was 
combined with chitosan to increase its stability. A study demonstrated that alginate-chitosan 
microspheres were able to prolong the retention time of azelastine in the cul-de-sac and to 
improve the therapeutic efficacy on in vivo using a rat model. Another study compared the effect 
of a chitosan coating of chitosan-alginate NPs for the delivery of 5-Flourouracil (5-FU). 
Interaction between corneal mucin layer and chitosan-alginate NPs was observed only with 
chitosan coating, resulting in higher bioavailability. A significantly higher level of 5-FU was 
found in aqueous solution of chitosan-alginate NPs compared to standard 5-FU solution [72]. 
Albumin. Albumin is a natural globular protein, commonly found in egg or blood plasma. 
Pilocarpine nitrate was encapsulated in egg albumin microspheres and showed a higher miotic 
response and duration [73]. Albumin was also combined with chitosan to formulate tetracaine-
loaded [74] and atropine-loaded [75] microspheres. These studies reported that 
microencapsulated tetracaine significantly increased the duration of action and effect of the 
drugs, compared to standard drug solution. 
Gelatin. Gelatin is a polymer derived from collagen, a natural constituent of the corneal tissue. 
Gelatin can interact with the negatively charged mucin layer due to the presence of positively 
charged amino groups in its structure. Moreover, the presence of arginine-glycine-aspartic acid 
sequence (RGD motif) provides cell adhesion properties [122]. Gelatin NPs have been 
formulated to successfully deliver timolol [76] and moxifloxacin [77] to the corneal surface. 
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Moreover, it has been shown that gelatin NPs possessed good stability, effective lowering of the 
IOP, high drug bioavailability and lack to irritation [76]. 
Hyaluronic acid. HA has not only been used as an ingredient for in situ gel forming formulation 
(as described in section 1.2) but has also been combined with other polymers to formulate NPs. 
For example, HA has been assessed as a coating of chitosan NPs in several studies. HA-coated 
chitosan NPs demonstrated a higher sustained release of dexamethasone compared to uncoated 
chitosan NPs, showing that the combination of HA with chitosan results in higher mucoadhesive 
properties by interacting with hyaluronan receptors on the corneal epithelia [78]. Moreover, HA-
modified chitosan NPs allowed successful delivery of dorzolamide and timolol on an in vivo 
albino rabbit model. A significantly higher reduction of IOP was observed when compared to a 
standard drug formulation as well as unmodified chitosan NPs [79]. 
Overall, NPs-based systems using natural polymers showed high adhesive properties and good 
biocompatibility allowing significantly higher drug retention and permeation through ocular 
tissues without inducing toxicity. However, natural polymers are also known to be easily 
degraded and their production process are limiting by low batch-to-batch reproducibility [4].  
 
3.1.2. Synthetic derived polymer-based nanoparticles  
Compared to natural polymers, synthetic polymers are generally more stable due to lower 
biodegradability rates, providing a slower and sustained release of drugs. Furthermore, synthetic 
polymers are more suitable for modifications such that it allows adjustment of their chemical and 
biological properties, physicochemical state, degradability and mechanical strength, according to 
the final biomedical applications [123]. However, synthetic polymers are also considered as less 
mucoadhesive than natural polymers due to the lack of functional groups that are able to interact 
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with the mucin layer, limiting their bioavailability [4]. Among the various synthetic polymers, 
Eudragit
®
, poly(lactic acid) (PLA), poly(lactic-co-glycolic) (PLGA) and polycaprolactone (PCL) 
showed particularly promising in vivo results for improving drug bioavailability and efficacy by 
topical administration. 
Eudragit
®
. Eudragit
®
 is the trade name used for synthetic copolymers derived from esters of 
acrylic and methacrylic acid. Eudragit
®
 polymers present great versatility according to the 
functional groups in the side-chain of the polymer. Eudragit
®
 RS100 and RL100 polymers or a 
combination of them have been commonly used as ocular DDS due to their positive charge, 
which can increase its precorneal retention time by interacting with the negatively charged mucin 
layer.  
These polymers have been used to successfully deliver a variety of drugs on the ocular surface 
including anti-inflammatory drugs (aceclofenac [81,82], diclofenac [83] and ibuprofen [84]), 
anti-glaucoma drugs (betaxolol [85], acetozalamide [86], brimonidine [87]), amphotericin B [88] 
and azelastine [89]. Recently, researchers developed a particularly interesting formulation based 
on Eudragit
®
/montmorillonite (Mt) microspheres to deliver betaxolol by topical administration. 
Drug release occurred in a 4-step process, allowing sustained release of betaxolol and thus longer 
bioavailability. In vitro studies showed an extended release duration of 12h with Eudragit
®
/Mt 
microspheres in comparison to standard betaxolol solution (2.5h) and only Eudragit
® 
microspheres (5h). Moreover, in vivo Draize rabbit eye test demonstrated a lower toxicity of 
betaxolol loaded in Eudragit
®
/Mt microspheres compared to betaxolol in standard solution [85].  
 
Poly(lactic acid) (PLA). PLA is a hydrophobic polyester synthetized by ring-opening 
polymerization of lactide. It is FDA-approved and has been widely used for various biomedical 
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applications [124]. However, the biodegradability rate of PLA is relatively low compared to 
other polymers [125], limiting its use for formulation of eye drops; therefore, it is usually grafted 
with other polymers to tailor its biodegradability [126]. 
In a recent study, Liu et al. developed NPs composed of PLA, dextran and phenylboronic (PBA) 
for the delivery of cyclosporin A on the ocular surface (Fig 4A) [127]. PBA is a molecule able to 
form covalent linkage with cis-diol groups of carbohydrates of the mucin layer [90]. In vivo 
studies performed on mice demonstrated that the PBA coating of the PLA-dextran NPs increased 
the retention time of the NPs when compared to conventional eye drops (Fig. 4B). Remarkably, 
it has also been shown that once a week dosage of NPs had similar therapeutic effect to three 
times a day dosage of the marketed formulation RESTASIS
®
. Another study assessed the use of 
NPs composed of PLA grafted with poly(methacrylic acid) (PMA) and PBA for the delivery of 
cyclosporin A (Fig. 4C) [91]. Different ratios of PLA:PMA:PBA were used including LMP-0 
(49.8:50.2:0), LMP-10 (51.3:46.7:3.8) and LMP-30 (58.1:35.2:10.4). Results showed that the 
addition of PBA increased the drug retention time without significant toxicity in an in vivo rat 
model (Fig. 4D). 
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Fig. 4. Increased drug retention by using poly(lactic acid) (PLA)-based nanoparticle 
systems. (A) Schematic of PLA-Dextran NPs the for the delivery of cyclosporin A (From [127]). 
(B) Images of rabbit eyes treated with free indocyanine green (ICG), NP−ICG (− PBA), and 
NP−ICG (+ PBA) obtained with confocal scanning laser ophthalmoscopy, (λex = 795 nm and λem 
= 810 nm). (C) Schematic of PLA-PMA-PBA NPs the for the delivery of cyclosporin A. (D) Slit 
lamp, fluorescence, and OCT images for LMP-0 (A,E,I), LMP-10 (B,F,J), LMP-30 (C,G,K), and 
negative control (D,H,L). 
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Poly(lactic-co-glycolic acid) (PLGA). PLGA is a FDA-approved synthetic copolymer of PLA 
and poly(glycolic acid) (PGA), known for its biodegradability and biocompatibility. Compared 
to PLA, the biodegradability rate of PLGA is relatively faster and its mechanical properties can 
be finely turned by modulating the PLA/PGA ratio. This polymer has particularly been used to 
formulate nanocarriers for topical ocular delivery.  
PLGA NPs were developed for the delivery of fluoromethalone [92] and aceclofenac [93]. No 
significant cytotoxicity of PLGA NPs were found in vitro and in vivo [128]. Compared to a 
standard drug formulation, PLGA NPs increased drug bioavailability, providing better drug 
efficacy. However, unlike other polymers, PLGA is not mucoadhesive [4]; therefore, it was 
combined with polyethylene glycol (PEG), a synthetic polymer able to interact with the mucin 
layer [129], to formulate mucoadhesive microspheres. These microspheres were used to deliver 
dorzolamide to the eyes of rabbits and showed a 35% greater maximum IOP decrease, and 2-fold 
increase in the duration of the IOP decrease, compared to TRUSOPT
®
. Interestingly, it has been 
found that a single drop of PLGA-PEG microspheres had a similar efficacy compared to 4 drops 
of TRUSOPT
® 
or 2 administrations of TRUSOPT
®
 at a 4-h interval [94].  
 
Polycaprolactone (PCL). PCL is another synthetic biodegradable polyester, particularly used in 
tissue engineering and drug delivery systems for varied biomedical applications. PCL has been 
especially used as nanocarriers for the delivery of carteolol [130], cyclosporine A [95] and 
indomethacin [96] to the anterior segment. In particular, PCL NPs showed a more pronounced 
IOP decrease compared to commercial carteolol eye drops [130].     
3.1.3. Combination of natural and synthetic polymers 
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As discussed previously, natural and synthetic polymers present specific advantages and 
disadvantages for ocular drug delivery. In order to gather the advantages of each source of 
polymers, some studies studied the combination of natural and synthetic polymers for the 
formulation of NPs-based DDS. 
Chitosan-based combinations. Synthetic polymers are generally not mucoadhesive, limiting the 
bioavailability on the corneal surface. In order to overcome this limitation, several formulations 
of synthetic polymers have been combined with chitosan, which has highly mucoadhesive 
properties. For example, chitosan was used as a coating for PLGA NPs and showed a sustained 
delivery of forskalin and thus, a greater IOP lowering effect and duration compared to standard 
forskalin solution. Chitosan-coated PLGA NPs have also been used to deliver fluocinolone to the 
anterior segment of rabbit eyes [98]. Results showed that chitosan coating increased and 
sustained drug release by PLGA NPs. Due to its hydrophilic properties, chitosan is not suitable 
to encapsulate hydrophobic drugs such as amphotericin B. Therefore, some researchers 
formulated amphiphilic NPs based on PLA-grafted-chitosan copolymer. An in vivo ocular 
pharmacokinetic study showed a prolonged precorneal retention time. Moreover, no sign of 
irritation was observed during the ocular irritation study [99].  Chitosan was also combined with 
PEG to formulate resveratrol-loaded NPs [100] and resveratrol and quercetin co-encapsulated 
NPs [101]. Both studies showed a sustained and enhanced reduction of IOP compared to 
standard drug solutions. Chitosan was also combined with PCL and PEG to formulate 
diclofenac-loaded nanosuspension [102]. In vivo pharmacokinetics studies showed enhanced 
precorneal retention time and penetration of the formulated nanosuspensions compared with 
commercial diclofenac eye drops.   
Jo
urn
al 
Pr
e-p
roo
f
Journal Pre-proof
  38 
Eudragit
®
-based combinations. Eudragit
®
/ethylcellulose (EC) NPs were designed to combine 
the advantages of the mucoadhesiveness, the controlled-release properties of EC and the positive 
charges of Eudragit
®
 that can interact with the negatively charged mucin layer [80]. This 
formulation was used to successfully deliver acetazolamide in normotensive rabbits. Results 
showed a greater IOP decrease and longer duration of the effect was displayed in normotensive 
rabbits compared with standard acetazolamide solution.  Eudragit
®
 NPs were also coated with 
HA in order to increase their mucoadhesiveness. However, no difference was observed for the 
simultaneous delivery of gatifloxacin and prednisolone, with or without HA coating [103].  
 
3.2.Polymeric/lipidic nanoparticles 
For the past decades, the use of lipidic vectors, such as liposomes or solid-lipid NPs, have widely 
been used for drug delivery in numerous biomedical applications, especially in ophthalmology. 
Due to its hydrophobicity, lipid carriers are suitable for encapsulation of hydrophobic drugs. 
Moreover, drugs encapsulated into lipophilic carriers can pass the corneal epithelial layer due to 
the solubilization of the carriers in the lipid cell membranes. However, lipidic formulations are 
known to be less stable and thus less suitable for sustained drug release. In recent years, addition 
of polymers to lipidic NPs formulations have raised special interest in order to increase the 
stability and mucoadhesiveness of NPs on the corneal surface.  
So far, chitosan is the polymer that is most combined with liposomes, micelles or solid lipidic 
NPs. Chitosan/lipidic NPs were formulated and showed an increased bioavailability and a 
sustained release of a variety of drugs, such as dexamethasone [105], timolol [106], amphotericin 
B [107,108], flurbiprofen [109,110], ofloxacin [111], natamycin [112], cyclosporin A [113], 
ciprofloxacin [114]. In a study by Ban et al., they compared the delivery of dexamethasone in 
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three different vectors: standard aqueous solution, negatively charged lipidic NPs and positively 
charged lipidic NPs. Interestingly, an in vivo study on rabbit eyes showed an increase of 
dexamethasone permeation of 2.7-fold and 1.8-fold for chitosan-modified and unmodified lipidic 
NPs, respectively [105]. These results display the importance of the effect of NP surface charge 
on the drug release and bioavailability (Fig. 5A). More interestingly, chitosan/lipidic NPs loaded 
with anti-glaucoma drugs demonstrated an increased IOP lowering effect compared to standard 
drug formulations, showing the correlation between drug bioavailability and its efficacy (Fig. 
5B-C) [104,106]. Moreover, no significant ocular irritation, damage or toxicity were observed by 
using chitosan/lipidic NPs [104,106–111].  
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Fig. 5. Increased drug retention and therapeutic effect using chitosan for the development 
of polymeric/lipidic NPs. (A) Schematic illustration of differently charged lipidic NPs carriers 
containing dexamethasone (From [105]). (B) The concentration–time curves of timolol (TM) in 
rabbit tears following topical administration of TM eye drops and liposomes with or without 
chitosan (CH) (mean ± SD, n = 3) (From [106]). (C) Percentage decrease in intraocular pressure 
(IOP) after administration of methazolamide solution, methazolamide-SLNs (solid lipids NPs), 
methazolamide-chitosan-SLNs, commercial eye drops and physical saline solution. (mean ± SD, 
n = 6) (From [104]). 
More recently, HA has also been combined with lipidic NPs to deliver moxifloxacin [115], 
tacrolimus [116] and doxorubicin [117]. Due to the ability of HA to target CD44 receptor on the 
corneal epithelial cells, these studies demonstrated an increase of drug bioavailability without 
significant toxicity. 
Synthetic polymers have also been used to increase the stability and sustained release of drugs 
delivered by micelles. In particular, diclofenac was loaded in PEG-PCL micelles and showed a 
2-fold increase of drug delivery in the aqueous humor of rabbit eyes compared with diclofenac 
PBS solution eye drops [118]. More recently, PEG-PLA micelles were formulated to deliver 
cyclosporine A in rabbit eyes, resulting a 4.5-fold increase of drug retention compared with 
0.05% cyclosporine A emulsion [119].   
4. Combination of several DDS 
As previously described, in situ forming gels and NPs-based systems represent promising 
strategies for ocular DDS. In order to combine the efficacy of each of these systems, 
combination of NPs and in situ gels has been investigated (Table 5).  
Jo
urn
al 
Pr
e-p
roo
f
Journal Pre-proof
  41 
Table 3. Drug delivery systems combining nanoparticles and in situ forming gels.  
NP types In situ gels Drug model  In vivo 
model 
In vivo study In vivo results Ref 
Chitosan Alginate-
HPMC 
Levofloxacin  Rabbit Precorneal retention by gamma 
scintigraphy. 
 
NPs-gel retained for longer duration at corneal surface and negligible 
radioactivity was observed in other organs compared with aqueous solution. 
[131] 
Chitosan and 
alginate 
 
Poloxamer Brimonidine  Mice Measurement of intraocular 
pressure by Tonolab tonometer. 
For chitosan NPs, AUCtotal values were found 4.14-fold and 5.09-fold higher 
for in situ gel and NPs-gel, respectively, compared with ALPHAGAN P®. For 
alginate NPs, AUCtotal values were found 3.72-fold and 4.66-fold higher for in 
situ gel and NPs-gel, respectively, compared with ALPHAGAN P®. 
 
[132] 
Chitosan-HA Chitosan 5-fluorouracil  Rabbit Determination of drug 
concentration in aqueous humor by 
HPLC. 
AUC(0-8h) was found 3.5-fold higher for in situ gel compared to standard eye 
drops. In situ gel achieved a Cmax of approximatively 0.65 µg/mL followed by 
a slow decline. NPs-gel had a plateau (0.25-0.3 µg/mL) in the time interval of 
0.5-7 hours. 
 
[133] 
PLGA Chitosan Levofloxacin  Rabbit Drug retention on corneal surface 
by gamma scintigraphy  
Marketed formulation reached into the systemic circulation via nasolacrimal 
drainage in 5h. Faster decline in radioactivity counts on the corneal surface for 
marketed formulation, compared with in situ gel, NPs and NPs-gel.   
 
[134] 
Albumin Poloxamer Curcumin  Rabbit Eye irritation test (Draize test). 
Determination of drug 
concentration in aqueous humor by 
HPLC. 
 
No sign of ocular irritation. Cmax was found to be 5.6-fold higher and AUC(0-
25h) 4.4-fold higher for NPs-gel compared to standard eye drop. 
 
[135] 
Poloxamer Poloxamer Dexamethasone  Rabbit Eye irritation test (Draize test). 
Determination of drug 
concentration in aqueous humor by 
HPLC. 
 
No sign of ocular irritation. AUC(0-12h) was found 2.8-fold and 2.86-fold 
higher for in situ gel and NPs-gel, respectively, compared with TOBRADEX®. 
Cmax was found to be 1.56-fold and 1.91-fold higher for in situ gel and NPs-gel, 
respectively, compared with TOBRADEX®.  
 
[136] 
Eudragit® Poloxamer-
HPMC 
Keratolac  Rabbit Eye irritation test (Draize test and 
winking method). Determination of 
drug concentration in aqueous 
humor by HPLC. 
No sign of ocular irritation and no abnormal winking compared with simulated 
tear fluid. AUC(0-8h) was found to be 2.03-fold and 2.51-fold higher for NPs 
and NPs-gel, respectively, compared with ACULAR®. Cmax was found to be 
1.41-fold and 1.20-fold higher for NPs and NPs-gel, respectively, compared 
with ACULAR®. 
 
[137] 
PLGA Carbomer Pranoprofen  Rabbit Eye irritation test (Draize test). 
Anti-inflammatory efficacy 
assessment by inflammation 
symptom scoring.  
No sign of ocular irritation. Better anti-inflammatory effica 
cy for NPs-gel compared to OFTALAR®. 
[138] 
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PLGA-
Eudragit® or 
PCL-
Eudragit® 
Carbomer Vancomycin  Rabbit Eye irritation test (Draize test). 
Determination of drug 
concentration in external ocular 
tissues by the disc diffusion. 
 
No sign of ocular irritation. AUC(0.25-24h) was found 2.14-fold and 2.33-fold 
higher for PLGA-Eudragit NPs-gel and PCL-Eudragit NPs-gel, respectively, 
compared with in situ gel. Cmax was found 8.73-fold and 10.06-fold higher for 
PLGA-Eudragit NPs-gel and PCL-Eudragit NPs-gel, respectively, compared 
with in situ gel. 
 
[139] 
pNIPAAm pNIPAAm Epinephrine  Rabbit Measurement of intraocular 
pressure by ophthalmic tonometer. 
In situ gel decreased IOP for at least 32h with a minimum of 6.1 mmHg at 6h. 
Standard eye drop decreased IOP for 6h with a minimum of 4.7 mmHg. 
 
[23] 
Liposomes HA Fluconazole  Rabbit Eye irritation test (Draize test). 
Determination of drug 
concentration in aqueous humor by 
HPLC. 
No sign of ocular irritation. Drug concentration was found above MIC 
(minimum inhibitory concentration, 8 µg/mL) for 24h for NPs-gel and for 6h 
for standard drug solution. 
 
 
[140] 
Liposomes Gellan gum Timolol  Rabbit Eye irritation test for a single and 
multiple dosing. Measurement of 
intraocular pressure by invagination 
tonometer. 
No sign of ocular irritation. Liposomes-gel decreased IOP from 30-300 min 
and a minimum of 11.96±0.74 mm/Hg was observed at 1h. Standard eye drops 
decreased IOP from 30-180min, with a minimum of 13.61 mm/Hg at 2h.  
[141] 
Abbreviations: AUC= Area Under the Curve; Cmax= Maximal concentration; HA= Hyaluronic acid; HPLC= High performance liquid 
chromatography; HPMC= Hydroxypropyl methyl cellulose; IOP= Intraocular pressure; NPs= Nanoparticles; PCL= Poly(epsilon-
caprolactone); PLGA= Poly(lactic-co-glycolic acid); pNIPAAm = Poly(N-isopropylacrylamide)
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Different combinations of NPs and in situ gels were formulated and allowed a successful 
delivery of a variety of drugs, such as antimicrobial drugs (levofloxacin [131,134],  vancomycin 
[139], fluconazole [140]), anti-glaucoma drugs (brimonidine [132], curcumin [135], 
dexamethasone [136], epinephrine [23], timolol [141]), anti-inflammatory drugs (keratolac 
[137], pranoprofen [138]) and 5-fluorouracil [133]. For example, chitosan NPs loaded in 
alginate/HPMC in situ gels increased precorneal retention time and limited the drainage via 
nasolacrimal conduct [131]. Similar results were obtained for the formulation of levofloxaxin-
loaded PLGA NPs combined with chitosan in situ gels. It has been shown that drainage was 
faster for the marketed formulation, compared with in situ gel, NPs and NPs-gel (Fig. 6A) [134].  
Also, several studies showed that the combination of NPs and in situ gels can improve drug 
permeation into ocular tissues and aqueous humor. Chitosan-HA NPs loaded in chitosan in situ 
gels exhibited a sustained delivery of 5-fluorouracil in rabbit aqueous humor compared to NPs or 
in situ gels only solution [133]. Improved drug penetration was also observed for albumin NPs 
loaded in poloxamer
®
 gel [135], poloxamer NPs loaded in poloxamer
®
 gel [136] and Eudragit
®
 
NPs loaded in poloxamer
®
/HPMC gel [137], PLGA-Eudragit
®
 and PCL-Eudragit
®
 loaded in 
Carbopol
®
 gel [139] and liposomes loaded in HA gel [140]. Compared to NPs or in situ gels 
only, their combination allowed to avoid a burst release and sustain the drug delivery to the 
aqueous humor (Fig. 6B). 
More interestingly, combination of NPs and in situ gels also provides a higher therapeutic effect. 
A formulation of PLGA NPs loaded in Carbopol
®
 in situ gel have been developed for delivery of 
pranoprofen. This formulation was compared with OFTALAR
®
, a marketed eye drop, in an in 
vivo rabbit model of inflammation induced by arachidonic acid sodium. Results demonstrated a 
lower inflammation score with NPs-gel compared to the OFTALAR
®
 [138]. Moreover, it has 
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been shown that liposomes loaded in gellan gum in situ gels allowed an increase of the IOP 
lowering effect and duration of timolol compared with standard eye drops [141]. Similar results 
in IOP lowering effect were observed for chitosan and alginate NPs loaded in poloxamer gel 
[132] and PNIPAAm NPs loaded in PNIPAAm gel [23] (Fig. 6C).  
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Fig. 6. Increased corneal retention and sustained release of drugs by combining in situ gels 
and NPs. (A) Dynamic gamma scintigraphy study showing percentage radioactivity remaining 
on cornea with time (blue-diamond shape) marketed, (green triangle shape) chitosan in situ gel, 
(red-square shape) nanosuspension, (purple-circle shape) nanoparticle laden in situ gel (From 
[134]). (B) Concentration of ketarolac in aqueous humor of rabbit eyes with time from the 
nanodispersion (E2) and in situ gel incorporated with E2 (NG2) compared to Acular® eye drops 
(From [137]). (C) The difference of IOP between two eyes (i.e. IOP lowering effect) for (a) 
linear PNIPAAm eye drops; and (b) linear PNIPAAm and nanoparticles mixture eye drops 
(From [23]).  
5. Challenges for the commercial development of new ophthalmic drug delivery systems 
Despite the high number of publications describing new ophthalmic DDS, relatively few 
products are finally commercialized. From bench to batch to market, numerous steps need to be 
achieved including preclinical and clinical development and pharmacovigilance. Regulations for 
commercialization of new ophthalmic DDS can vary according to the country. Here, we will 
describe the regulatory affairs of the three regions where most eye drops are currently 
commercialized: the United States, Europe and Japan. 
5.1.Regulatory affairs 
Eye drops are defined as medicinal products, if used through pharmaceutical, immunological or 
metabolic action, or as medical devices if used for cleaning, rinsing or hydrating [142]. Eye 
drops containing polymers (HA, cellulose derivatives or others) such as artificial tears are 
considered as medical devices because their action is limiting to hydrate the corneal surface. Due 
to the presence of active pharmaceutical drugs in the formulation, DDS-based eye drops are 
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considered as medicinal products. To commercialize a new eye drop formulation, pharmaceutical 
companies must prove the efficacy and safety of their formulations by performing preclinical and 
clinical studies. After these processes, they can ask for marketing authorization to the relevant 
competent authority of the country where they want to sell the product, particularly the European 
Medicines Agency (EMA, Europe), the Food and Drug Administration (FDA, US) and the 
Ministry of Health, Labour and Welfare (Japan).  
5.2. Production process and quality controls 
One of the most challenging steps for commercialization of new DDS is the production of large-
scale batches. These batches must be produced under Good Manufacturing Practices (GMPs), 
which are guidelines that ensure quality and reproducibility from batch-to-batch. The 
modification of manufacturing process between academic laboratories and industry can 
significantly affect the product characteristics and thus, its efficacy and safety [143]. The 
Pharmacopeia is a regulatory publication describing all criteria necessary for the manufacturing 
of medicinal products and the methods of analysis to guarantee quality controls. A complete 
description of the product must be provided according to the Pharmacopeia of the relevant 
country, including biological and chemical characterizations, manufacturing process, and quality 
controls. Biological and chemical criteria include product composition and physicochemical 
properties (appearance, color, pH, osmolarity, drug concentration, stability, sterility and purity). 
For NP-based systems, more specific criteria need to be assessed such as particle 
size/distribution, surface characterization (zeta potential, functionality and surface chemistry), 
morphology, drug loading, and drug encapsulation [144].  
Particle size. A particle size that exceed 10 µm cannot be absorbed by ocular tissues, nor 
eliminated through the nasolacrimal conduct, which can cause ocular irritability [145]. Thereby, 
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the United States Pharmacopeia requires less than 50 particles superior or equal to 10 µm 
diameter per mL of solution.  
Stability. Stability tests are required to guarantee that the formulation presents the same 
properties and characteristics within specified limits and throughout its period of storage and use, 
that it possessed at the time of its manufacturing. Natural materials, such as chitosan or gelatin, 
are known to be less stable and more degradable than synthetic polymers [146], explaining the 
reason for relatively low use of natural materials in ophthalmic formulations. Maintaining the 
stability of nano-emulsions and nano-suspensions can also be particularly challenging due to the 
risk of aggregation and degradation of NPs [147]. 
Sterility. Different techniques of sterilization can be used such as sterile filtration, autoclaving, 
irradiation or treatment with ethylene oxide and gas plasma. Each of these techniques has 
advantages and disadvantages that need to be considered according to the properties of the active 
and inactive ingredients of the formulation. Irradiation with γ-radiation, electron beam or X-rays 
are the techniques most used for ophthalmic preparations because no heat or chemicals are 
required [4,148]. Moreover, benzalkonium chloride (BAK) is widely used in multidose eye drops 
to maintain sterility between uses. However, several studies showed that BAK can have side 
effects for ocular tissues, resulting in complications such as dry eye, trabecular meshwork 
degeneration and ocular inflammation [149,150]. An alternative to BAK is the use of single-dose 
vials or multidose bottles fitted with an antimicrobial membrane. 
Purity. The different Pharmacopeia recommend that endotoxin limits cannot exceed 0.5 EU/mL 
for ophthalmic preparations. As described previously, natural polymers, such as chitosan or 
alginate, have particularly interesting properties for use in ophthalmic DDS. However, because 
they are extracted from natural sources, impurities such as endotoxins could be present and cause 
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immunogenic reactions [151]. These impurities could explain why chitosan is not used in 
marketed formulations, despite its numerous advantages for ocular drug delivery.  
5.3.Preclinical and clinical studies 
The goal of preclinical and clinical studies is to assess the efficacy and safety of the formulation 
from pharmacology, pharmacokinetics and toxicology aspects. In the case of NP-based systems, 
preliminary in vitro tests are required including drug release, therapeutic activity, mechanism of 
action, cellular uptake and immunology [143]. It is usually recommended to perform preclinical 
studies on two different in vivo animal models, rodent and non-rodent. Rabbit animal models are 
the most frequently used for topical ophthalmic drugs and DDS, followed by dog and rat models. 
In preclinical studies, the formulation is applied on the animal eye and the adapted dosing and 
side effects are determined. Larger animal models have the advantage of closer anatomical and 
size proximity to human eyes, but are more expensive, and in the case of some species (e.g. 
rabbits, dogs) suffer from fewer reagents such as specific antibodies for pharmacodynamic 
studies. For eye drops, these pharmacokinetic studies are generally performed by quantification 
of the drug in plasma, tears and other ocular tissues, at different time points after instillation of 
the eye drop. Preclinical studies present limitations such as the low number of animals used and 
the short observation period. Furthermore, the difference in size and shape of ocular tissues, 
metabolic activity, and blinking rate between animal models and humans may also limit the 
extrapolation of such data to humans.  
6. Concluding perspectives 
Topical medications are the preferred method of drug delivery for numerous ocular disorders,  
including glaucoma which represents the third cause of blindness, with 105 million cases 
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worldwide [152]. Despite its ease of use and relatively low cost compared to other treatments, 
the use of eye drops requires a strict dose regimen. Moreover, the high (albeit highly variable) 
concentrations that can be achieved in ocular tissues can cause side effects that range from 
relatively minor tolerability issues to significant toxicity side-effects such as the increasingly 
appreciated toxic effects of anti-glaucoma medications on the ocular surface epithelium. Poor 
tolerability profiles are usually associated with poor patient compliance, a major limiting factor 
for many topical medications.  
Over the past few decades, a variety of DDS have been marketed for treatment of ocular 
conditions. In situ gelling systems are cost-effective, easy to produce, and generally 
biocompatible, making them good candidates for the development of ocular DDS. Beside its 
advantages, a limited number of in situ gels are currently in clinical use. In most of the studies 
detailed herein, significant improved therapeutic effects have been observed using gelling 
systems. Nevertheless, these improvements are usually not sufficient to significantly reduce the 
drug dose regimen. Among the marketed formulations containing gelling systems, similar side 
effects are observed compared with standard formulations. For these reasons, the development of 
new types of DDS shows special interests given the numerous published papers on these fields 
over the last decade. 
In situ gels have shown their potential to increase the retention time of drugs on the ocular 
surface, thereby improving their therapeutic effect. Due to the sol-gel transition, the viscosity of 
in situ forming gels increases upon contact with the eye, limiting drug elimination via 
nasolacrimal drainage. Conversely, increase in viscosity can potentially also induce higher 
lacrimation that can accelerate drug elimination. Moreover, for some stimuli-responsive 
materials, the gelation efficiency is relatively weak. High concentrations of materials or a 
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combination of several materials have been used that can increase their toxicity. Highly viscous 
gels can also induce visual blur, a limiting factor in their use. 
Compared to in situ forming gels, NP-based systems have shown their ability to increase both 
drug retention and permeation through ocular tissues with limited increase of the formulation 
viscosity. Moreover, NP-based systems allow modification of the pharmacokinetics of drug 
release by prevention of a burst release effect of the drug, particularly of interest in cases of 
chronic diseases, such as glaucoma. Overall, cationic carriers showed better performance than 
anionic or non-ionic carriers, due to the electrostatic interactions with the negatively-charged 
mucin layer of the corneal surface. NP-based systems have also been incorporated in in situ 
forming gels and results showed better performance than NPs or gels alone. This trend of 
combining several DDS suggests that none of these systems alone seems to be efficient enough 
to achieve a significantly better performance.  
Despite promising results, the biggest challenge will be to develop these DDS for clinical use. 
Despite their excellent adhesive and biocompatible properties, the use of natural polymers 
(especially from animal origin) in eye drops formulations considerably complicates the 
production process. For this reason, problems of stability, sterility and purity need to be 
anticipated at the very early stage of the product development. Therefore, more research and 
development need to be done in order to significantly improve methods of preparation and 
storage guaranteeing efficacy and safety of ocular DDS.    
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Highlights 
• Eye drops have limited efficacy due to the unique 
physio-anatomy of the eye 
• Advances in polymer science have led to 
development of new drug delivery systems 
• These systems show improved ocular drug 
penetration and retention in animal models 
• Increased bioavailability could reduce dose regimen 
and side effects for patients 
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• Better manufacturing processes are essential for 
successful clinical translation 
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